Advances in Pediatric HIV-1 Cure Therapies and Reservoir Assays

Viruses. 2022 Nov 23;14(12):2608. doi: 10.3390/v14122608.

Abstract

Significant advances in the field of HIV-1 therapeutics to achieve antiretroviral treatment (ART)-free remission and cure for persons living with HIV-1 are being made with the advent of broadly neutralizing antibodies and very early ART in perinatal infection. The need for HIV-1 remission and cure arises due to the inability of ART to eradicate the major reservoir for HIV-1 in resting memory CD4+ T cells (the latent reservoir), and the strict adherence to lifelong treatment. To measure the efficacy of these cure interventions on reservoir size and to dissect reservoir dynamics, assays that are sensitive and specific to intact proviruses are critical. In this review, we provided a broad overview of some of the key interventions underway to purge the reservoir in adults living with HIV-1 and ones under study in pediatric populations to reduce and control the latent reservoir, primarily focusing on very early treatment in combination with broadly neutralizing antibodies. We also summarized assays currently in use to measure HIV-1 reservoirs and their feasibility and considerations for studies in children.

Keywords: cure strategies; intact provirus; pediatric HIV-1 infection; reservoir assays.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • Broadly Neutralizing Antibodies
  • CD4-Positive T-Lymphocytes
  • Child
  • Female
  • HIV Infections*
  • HIV Seropositivity*
  • HIV-1*
  • Humans
  • Pregnancy
  • Proviruses
  • Viral Load
  • Virus Latency

Substances

  • Broadly Neutralizing Antibodies
  • Anti-Retroviral Agents